Label (71610 0798 15)
Rosuvastatin Tablet, Film Coated
Product Images NDC 71610-798
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rosuvastatin (NDC 71610-798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena (Aphena)
Figure-01 (Figure 1)
This description provides data on the effectiveness of a treatment compared to a placebo. The treatment group had 8901 participants at the start, decreasing over the years to 8412, 3892, 1352, 543, and 156 individuals. In contrast, the placebo group started with 8901 individuals and decreased to 8353, 3872, 1333, 534, and 173 participants over the same period. The treatment showed a statistically significant difference with a hazard ratio of 0.56 (95% CI 0.46-0.69) and a p-value of less than 0.001. The data also includes the number at risk over the years for both groups.*
Figure-02 (Figure 2)
This is a statistical analysis comparing the effectiveness of Rosuvastatin 20mg versus Placebo 20mg in preventing cardiovascular events. The study involved 8901 participants and evaluated various endpoints such as Cardiovascular Death, Nonfatal Stroke, Nonfatal MI, Hospitalized unstable Angina, and Arterial revascularization. Results show significant differences in event rates between the two groups, with Rosuvastatin demonstrating lower hazard ratios for most outcomes compared to the placebo.*
Figure-02 (Figure 3)
Structural Formula (Rosuvastatin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
